Functional iron status of chronic kidney disease patients at the University of Ilorin Teaching Hospital, Ilorin, Nigeria

Sanni, Emmanuel O; Olawumi, Hannah O; Durotoye, Idayat A; Olanrewaju, Timothy O; Babatunde, Abiola S; Olasunkanmi, A Shittu; Biliaminu, Sikiru A; Omokanye, Khadijat O; Ogunfemi, Mutiat Kehinde; Akinwumi, Olabisi O; Oyedepo, Dapo S; Adepoju, Ayodeji M.
African Health Sciences ; 22(3): 718-725, 2022-10-26. Figures, Tables
Artículo en Inglés | AIM | ID: biblio-1401990

Documentos relacionados

  1. Mechanisms of hemoglobin cycling in anemia patients treated with erythropoiesis-stimulating agents.
  2. Relationships among the Dosage of Erythropoiesis-Stimulating Agents, Erythropoietin Resistance Index, and Mortality in Maintenance Hemodialysis Patients.
  3. Changes in Metabolomic Profiles Induced by Switching from an Erythropoiesis-Stimulating Agent to a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor in Hemodialysis Patients: A Pilot Study.
  4. Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D).
  5. The Use of Anemia Control Model Is Associated with Improved Hemoglobin Target Achievement, Lower Rates of Inappropriate Erythropoietin Stimulating Agents, and Severe Anemia among Dialysis Patients.
  6. Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient.
  7. Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients.
  8. The Effect of Biosimilar Prescription Targets for Erythropoiesis-Stimulating Agents on the Prescribing Behavior of Physicians in Germany.
  9. Quality of life: a crucial aspect for the patients, a neglected goal in the treatment of anemia in patients with CKD.
  10. The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.